If [177Lu]Lu-PSMA treatment is administered to individuals with thyroid cancer, the likelihood of encountering xerostomia is probably further elevated due to potential residual damage to the thyroid glands from prior 131I therapies. The gene discussed is FOLH1; the disease is thyroid gland carcinoma.